We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Healthcare Stocks' Q2 Earnings on Aug 8: BKD, BIOS, DVA
Read MoreHide Full Article
Medical is one of the eight sectors in the S&P 500 cohort that is expected to record growth in earnings in the second quarter. The sector is likely to post earnings growth of 4.4% on revenue improvement of 7.7%.
We note that 414 S&P companies have already reported their quarterly numbers, with 70.3% of them beating EPS estimates and 51.9% surpassing the top-line estimate.
As per the latest Zacks Earnings Trend report, overall second-quarter earnings for the S&P 500 companies are expected to be down 3.1% year over year on revenue decline of 0.4%.
Healthcare is an important component of the Medical sector and is expected follow the earnings growth trajectory in the quarter.
Here, we take a look at three healthcare stocks scheduled to report their second-quarter figures on Aug 8:
Brookdale Senior Living Inc (BKD - Free Report) is the leading operator of senior living communities throughout the United States. We believe impressive revenue contribution from the senior housing segment, strong focus on core business and exclusive ‘senior-living’ solutions are the key drivers.
Notably, the recent announcement of Brookdale to rationalize its portfolio by divesting 44 communities is a positive. Meanwhile, the company has disposed a total of 30 communities with 2,594 units, either through sales or lease terminations. We expect these initiatives to reduce operational disruptions and fortify Brookdale’s core business.
However, our proven model does not conclusively show that the company is likely to beat earnings, given the combination of a Zacks Rank #4 (Sell) and Earnings ESP of 0.00%. We note the Most Accurate estimate and Zacks Consensus Estimate for the company is pegged at 59 cents.
As per our proven model, a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) to beat estimates. Simultaneously, we caution against stocks with a Zacks Rank #4 or 5 (Sell-rated) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
BioScrip Inc is a major national provider of infusion and home care management solutions. The Infusion platform, addition of new hospital-transitional care contracts and exceptional clinical management capabilities are likely to drive growth.
Moreover, the recent announcement to acquire all the assets of Home Solutions is a major positive, which should help BioScrip to take over a leading position in the Home Infusion market.
Nevertheless, our proven model does not conclusively show that the company is likely to beat estimates, given the combination of a Zacks Rank #2 and Earnings ESP of 0.00%.
This is because both the Most Accurate estimate and the Zacks Consensus Estimate for the company is pegged at a loss of 9 cents.
Headquartered in Denver, CO, DaVita HealthCare Partners Inc (DVA - Free Report) is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD).
An improved performance by the Kidney Care segment, strategic acquisitions, collaborations with local hospitals, strong financial position and a compelling inorganic growth story are the key accelerators for growth.
However, our proven model does not conclusively show that the company is likely to beat earnings, given the combination of a Zacks Rank #4 and Earnings ESP of +2.04%. We note that the Most Accurate estimate for DaVita stands at $1.00, while the Zacks Consensus Estimate is pegged at 98 cents.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Healthcare Stocks' Q2 Earnings on Aug 8: BKD, BIOS, DVA
Medical is one of the eight sectors in the S&P 500 cohort that is expected to record growth in earnings in the second quarter. The sector is likely to post earnings growth of 4.4% on revenue improvement of 7.7%.
We note that 414 S&P companies have already reported their quarterly numbers, with 70.3% of them beating EPS estimates and 51.9% surpassing the top-line estimate.
As per the latest Zacks Earnings Trend report, overall second-quarter earnings for the S&P 500 companies are expected to be down 3.1% year over year on revenue decline of 0.4%.
Healthcare is an important component of the Medical sector and is expected follow the earnings growth trajectory in the quarter.
Here, we take a look at three healthcare stocks scheduled to report their second-quarter figures on Aug 8:
Brookdale Senior Living Inc (BKD - Free Report) is the leading operator of senior living communities throughout the United States. We believe impressive revenue contribution from the senior housing segment, strong focus on core business and exclusive ‘senior-living’ solutions are the key drivers.
BROOKDALE SENR Price and EPS Surprise
BROOKDALE SENR Price and EPS Surprise | BROOKDALE SENR Quote
Notably, the recent announcement of Brookdale to rationalize its portfolio by divesting 44 communities is a positive. Meanwhile, the company has disposed a total of 30 communities with 2,594 units, either through sales or lease terminations. We expect these initiatives to reduce operational disruptions and fortify Brookdale’s core business.
However, our proven model does not conclusively show that the company is likely to beat earnings, given the combination of a Zacks Rank #4 (Sell) and Earnings ESP of 0.00%. We note the Most Accurate estimate and Zacks Consensus Estimate for the company is pegged at 59 cents.
As per our proven model, a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) to beat estimates. Simultaneously, we caution against stocks with a Zacks Rank #4 or 5 (Sell-rated) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
BioScrip Inc is a major national provider of infusion and home care management solutions. The Infusion platform, addition of new hospital-transitional care contracts and exceptional clinical management capabilities are likely to drive growth.
Moreover, the recent announcement to acquire all the assets of Home Solutions is a major positive, which should help BioScrip to take over a leading position in the Home Infusion market.
BIOSCRIP INC Price and EPS Surprise
BIOSCRIP INC Price and EPS Surprise | BIOSCRIP INC Quote
Nevertheless, our proven model does not conclusively show that the company is likely to beat estimates, given the combination of a Zacks Rank #2 and Earnings ESP of 0.00%.
This is because both the Most Accurate estimate and the Zacks Consensus Estimate for the company is pegged at a loss of 9 cents.
Headquartered in Denver, CO, DaVita HealthCare Partners Inc (DVA - Free Report) is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD).
An improved performance by the Kidney Care segment, strategic acquisitions, collaborations with local hospitals, strong financial position and a compelling inorganic growth story are the key accelerators for growth.
DAVITA HEALTHCR Price and EPS Surprise
DAVITA HEALTHCR Price and EPS Surprise | DAVITA HEALTHCR Quote
However, our proven model does not conclusively show that the company is likely to beat earnings, given the combination of a Zacks Rank #4 and Earnings ESP of +2.04%. We note that the Most Accurate estimate for DaVita stands at $1.00, while the Zacks Consensus Estimate is pegged at 98 cents.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>